KR910011854A - R-(-)-1-(5-하이드록시헥실)-3-메틸-7-프로필크산틴, 이의 제조방법 및 이를 함유하는 약제 - Google Patents

R-(-)-1-(5-하이드록시헥실)-3-메틸-7-프로필크산틴, 이의 제조방법 및 이를 함유하는 약제 Download PDF

Info

Publication number
KR910011854A
KR910011854A KR1019900021298A KR900021298A KR910011854A KR 910011854 A KR910011854 A KR 910011854A KR 1019900021298 A KR1019900021298 A KR 1019900021298A KR 900021298 A KR900021298 A KR 900021298A KR 910011854 A KR910011854 A KR 910011854A
Authority
KR
South Korea
Prior art keywords
methyl
propylxanthine
hydroxyhexyl
carboxylic acid
aprotic solvent
Prior art date
Application number
KR1019900021298A
Other languages
English (en)
Other versions
KR0179654B1 (ko
Inventor
푸러 하랄트
게베르트 울리히
루돌피 칼
Original Assignee
펜스케, 라피세
훽스트 아크티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 펜스케, 라피세, 훽스트 아크티엔게젤샤프트 filed Critical 펜스케, 라피세
Publication of KR910011854A publication Critical patent/KR910011854A/ko
Application granted granted Critical
Publication of KR0179654B1 publication Critical patent/KR0179654B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/182—Heterocyclic compounds containing nitrogen atoms as the only ring heteroatoms in the condensed system

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

내용 없음

Description

R-(-)-1-(5-히이드록시 헥실)-3-메틸-7-프로필크산틴, 이의 제조방법 및 이를 함유하는 약제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (9)

  1. R-(-)-1-(5-하이드록시헥실)-3-메틸-7-프로필크산틴.
  2. a) 빵 효모(Saccharomyces cerevisiae)를 사용하여 1-(5-옥소헥실)-3-메틸-7-프로필크산틴을 S-(+)-(5-하이드록시헥실)-3-메틸-7-프로필 크산틴으로 환원시키고, b) 이를 배위 역젖에 의해 R-(-)-1-(5-하이드록시헥실)-3-메틸-7-프로필크산틴으로 전환시킴을 포함하는 제1항의 화합물을 제조하는 방법.
  3. 제2항에 있어서, 배위의 역전을 비양자성 용매중에서 3급 포스핀, 카복실산 및 디알킬 이조디카복실레이트의 반응에 의해 수행하고, 사용된 카복실산의 에스테르 형태인 R-(-)-거울상 이성체를 함유하는 반응생성물을 가용매분해하며 가용매분해 생성물을 공지의 방법으로 후처리하는 방법.
  4. 제3항에 있어서, 트리페닐포스핀을 3급 포스핀으로 사용하고, 벤조산을 카복실산을 사용하여 디에틸 이조디카복실레이트를 디알킬 이조디카복실레이트로 사용하고, 테트라하이드로푸란을 비양자성 용매로 사용하며 가용매분해는 탄산칼륨의 존재하에 가메탄올분해의형태로 수행하는 방법.
  5. 제2항에 있어서, 배위 역전의경우, S-(+)-거울상 이성체를 (1) 필요에 따라 비양자성 용매 중에서 염기의 존재하에 유기 설포닐 할라이드를 사용하여 상응하는 설폰산 에스테르로 전환시키고, (2) 상기 에스테르를 비양자성 용매중에서 지방족 카복실산의 알칼리 금속염과 반응시켜 상응하는 카복실산 에스테르를 수득하며(이때, 배위의 역전이 일어난다). (3)염기성 물질의 존재하에 알코올성 또는 수용성 용매 중에서 가용매분해에 의해 상기 카복실산 에스테르로부터 제1항의 화합물을 유리시키는 방법.
  6. 제5항에 있어서, 단계(1)에서 유기 설포닐 할라이드로서 메탄설포닐 클로라이드 또는 p-톨루엔설포닐 클로라이드를 사용하고, 염기로서 트리에틸아민을 사용하며 비양자성 용매로서 피리딘 및/또는 디클로로 메탄올 사용하고, 단계(2)에서 지방족 카복실산의 알칼리 금속염으로서 세슘 프로피오네이트를 사용하고 비양자성 용매로서 디메틸포름아미드 및/또는 디메틸 설폭사이드를 사용하며, 단계(3)에서 용매로서 메탄올을 사용하고, 염기성 물질로서 탄산칼륨을 사용하는 방법.
  7. R-(-)-1-(5-하이드록시헥실)-3-메틸-7-프로필크산틴을 함유하는 약제.
  8. 제7항에 있어서, 뇌맥관 장애의 예방 및 치료용으로서의 약제.
  9. 뇌맥관 장애의 예방 및 치료용으로서의 R-(-)-1-(5-하이드록시헥실)-3-메틸-7-프로필크산틴의 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900021298A 1989-12-23 1990-12-21 R-(-)-1-(5-하이드록시헥실)-3-메틸-7-프로필크산틴, 이의 제조방법 및 이를 함유하는 약제 KR0179654B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DEP3942871.0 1989-12-23
DEP39428710 1989-12-23
DE3942871A DE3942871A1 (de) 1989-12-23 1989-12-23 R-(-)-1-(5-hydroxyhexyl)-3-methyl-7-propylxanthin, verfahren zu dessen herstellung und diese verbindung enthaltende arzneimittel

Publications (2)

Publication Number Publication Date
KR910011854A true KR910011854A (ko) 1991-08-07
KR0179654B1 KR0179654B1 (ko) 1999-03-20

Family

ID=6396380

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900021298A KR0179654B1 (ko) 1989-12-23 1990-12-21 R-(-)-1-(5-하이드록시헥실)-3-메틸-7-프로필크산틴, 이의 제조방법 및 이를 함유하는 약제

Country Status (9)

Country Link
US (2) US5407815A (ko)
EP (1) EP0435153B1 (ko)
JP (1) JPH07107063B2 (ko)
KR (1) KR0179654B1 (ko)
AT (1) ATE137237T1 (ko)
DE (2) DE3942871A1 (ko)
DK (1) DK0435153T3 (ko)
ES (1) ES2086359T3 (ko)
GR (1) GR3019860T3 (ko)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW209834B (ko) * 1991-12-11 1993-07-21 Hoechst Ag
US5648357A (en) * 1992-03-04 1997-07-15 Cell Therapeutics, Inc. Enatiomerically pure hydroxylated xanthine compounds
US5580873A (en) * 1992-03-04 1996-12-03 Cell Therapeutics, Inc. Enatiomerically pure hydroxylated xanthine compounds to treat proliferative vascular diseases
JP2753395B2 (ja) * 1992-03-04 1998-05-20 セル・セラピューティックス・インコーポレーテッド 鏡像異性体ヒドロキシル化キサンチン化合物
US5780476A (en) * 1992-11-16 1998-07-14 Cell Therapeutics, Inc. Hydroxyl-containing xanthine compounds
ES2260756T3 (es) * 1992-12-31 2006-11-01 Heska Corporation Proteina y peptidos alergenicos de caspa de perro y sus usos.
WO1994016704A1 (en) * 1993-01-19 1994-08-04 Cell Therapeutics, Inc. Oxime-substituted therapeutic compounds
US5620676A (en) * 1994-03-08 1997-04-15 The United States Of America As Represented By The Department Of Health And Human Services Biologically active ATP analogs
WO2012031072A1 (en) * 2010-09-01 2012-03-08 Concert Pharmaceuticals, Inc. Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation
US9074233B2 (en) 2010-09-01 2015-07-07 Concert Pharmaceuticals, Inc. Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4576947A (en) * 1967-12-16 1986-03-18 Hoechst Aktiengesellschaft Pharmaceutical compositions
DE2335170C2 (de) * 1973-07-11 1989-07-20 Hoechst Ag, 6230 Frankfurt 1,3-Dialkyl-7-(hydroxyalkyl)-xanthine, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
US4515795A (en) * 1968-11-25 1985-05-07 Hoechst Aktiengesellschaft Pharmaceutical compositions
DE2366527C2 (ko) * 1973-07-11 1987-08-27 Hoechst Ag, 6230 Frankfurt, De
US4517795A (en) * 1979-11-28 1985-05-21 Deere & Company Bale-shape gauge for baler for forming cylindrical bales
US4857468A (en) * 1985-04-13 1989-08-15 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Process for preparing optically active 2-halo-1-phenyl ethanol
DK649787A (da) * 1986-12-23 1988-06-24 Hoffmann La Roche Fremgangsmaade til fremstilling af optisk aktive smoersyrederivater
DE3942872A1 (de) * 1989-12-23 1991-06-27 Hoechst Ag Verfahren zur enantioselektiven darstellung von ((omega)-1)-hydroxyalkylxanthinen

Also Published As

Publication number Publication date
DE3942871A1 (de) 1991-06-27
KR0179654B1 (ko) 1999-03-20
JPH07107063B2 (ja) 1995-11-15
EP0435153B1 (de) 1996-04-24
DE3942871C2 (ko) 1992-11-05
EP0435153A2 (de) 1991-07-03
US5478831A (en) 1995-12-26
DK0435153T3 (da) 1996-08-05
DE59010302D1 (de) 1996-05-30
US5407815A (en) 1995-04-18
GR3019860T3 (en) 1996-08-31
JPH04210688A (ja) 1992-07-31
ES2086359T3 (es) 1996-07-01
EP0435153A3 (en) 1992-05-13
ATE137237T1 (de) 1996-05-15

Similar Documents

Publication Publication Date Title
KR910011854A (ko) R-(-)-1-(5-하이드록시헥실)-3-메틸-7-프로필크산틴, 이의 제조방법 및 이를 함유하는 약제
Mori Revision of the absolute configuration of A-factor: the inducer of streptomycin biosynthesis, basing on the reconfirmed (R)-configuration of (+)-paraconic acid
NL7803999A (nl) Werkwijze voor de continue bereiding van polyethyleen- tereftalaat door direkte verestering van tereftaalzuur met ethyleenglycol, gevolgd door verdere polymerisatie.
FI884626A0 (fi) Menetelmä terapeuttisesti käyttökelpoisen 4H-1-bentsopyran-4-onijohdoksen tai sen suolan valmistamiseksi ja menetelmässä käyttökelpoinen välituote
KR840006812A (ko) 해중합된 과황산염 헤파린의 제조방법
NL7509249A (nl) Werkwijze voor de bereiding van nieuwe 5,9-(beta)-di- gesubstitueerde 2-tetra-hydrofurfuryl-6,7-benzo- morfanen en zuuradditiezouten daarvan, werkwijze voor de bereiding van farmaceutische preparaten die de genoemde stoffen als werkzaam bestanddeel bevatten, alsmede gevormde farmaceutische prepa- raten verkregen volgens de laatstgenoemde werkwijze.
KR920701177A (ko) 3-아릴옥사졸리디논 유도체, 그의 제조 방법 및 그의 치료 용도
KR910012260A (ko) (w-1)-하이드록시알킬크산틴의 에난티오선택적 제조방법
ATE87916T1 (de) 3-desmethyl-4-fluor-mevalonsaeurederivate, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen, ihre verwendung und zwischenprodukte.
SE7713578L (sv) Kemiskt forfarande
IT1165252B (it) Procedimento di purificazione dell'acido ursodesossicolico attraverso nuovi derivati
US7321057B2 (en) Method for manufacturing prostaglandin analogue
ES2010714B3 (es) Procedimiento de preparacion de tetrahidro-1,1,2,2 perfluoroalcanolesy de sus esteres.
KR927003561A (ko) β-페닐이소세린의 유도체, 그의 제조 및 이용
DE69616470D1 (de) Verfahren zur Herstellung von Dialkylsuccinylsuccinaten
AU532219B2 (en) Process for making allylic esters of tetrabromophthalic acid
HUP9802096A2 (hu) Piperidino-alkanol-vegyületeket tartalmazó orális adagolású oldat formájú gyógyszerkészítmény, és eljárás előállítására
JPS5795995A (en) Phosphonoformaldehyde, manufacture and use as intermediate product for producing drug
Hudlický The synthesis of γ-fluoroglutamic acid
EP0346852A3 (de) Verfahren zur Herstellung von 4-chlor-3-alkoxy-but-2E-en-säurealkylester
TNSN88070A1 (fr) Procede de preparation de l'acide (pyridyl-3)-3-1h, 3h-pyrrolo (1,2-c) thiazolecarboxylique-7dextrogyre
SE7906681L (sv) Ftalazonderivat
KR880006223A (ko) 12- 할로겐화 포스콜린 유도체, 중간체 및 이의 제조방법, 및 약제로서의 이의 용도
IT998723B (it) Processo per la preparazione di esteri dell acido clorocarbonico
ATE226190T1 (de) Verfahren zur herstellung von 13-cis-retinsäure

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee